Advantage Alpha Capital Partners LP Sells 43,709 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

Advantage Alpha Capital Partners LP cut its holdings in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 34.5% in the third quarter, Holdings Channel reports. The institutional investor owned 82,883 shares of the company’s stock after selling 43,709 shares during the quarter. Advantage Alpha Capital Partners LP’s holdings in MiMedx Group were worth $491,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Paradigm Capital Management Inc. NY raised its stake in MiMedx Group by 6.6% during the 2nd quarter. Paradigm Capital Management Inc. NY now owns 4,167,200 shares of the company’s stock valued at $28,879,000 after purchasing an additional 258,700 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of MiMedx Group by 6.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,435,397 shares of the company’s stock worth $8,483,000 after purchasing an additional 92,726 shares during the period. Dimensional Fund Advisors LP raised its position in shares of MiMedx Group by 47.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,292,822 shares of the company’s stock valued at $8,958,000 after buying an additional 413,443 shares during the last quarter. Harbor Capital Advisors Inc. lifted its stake in shares of MiMedx Group by 299.9% in the third quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company’s stock valued at $6,074,000 after buying an additional 770,744 shares during the period. Finally, Royce & Associates LP grew its position in MiMedx Group by 5.3% during the third quarter. Royce & Associates LP now owns 972,853 shares of the company’s stock worth $5,750,000 after buying an additional 48,539 shares in the last quarter. 79.15% of the stock is owned by institutional investors.

Analysts Set New Price Targets

MDXG has been the subject of a number of research reports. Craig Hallum reduced their price objective on MiMedx Group from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. Cantor Fitzgerald reiterated an “overweight” rating and set a $11.00 price target on shares of MiMedx Group in a research note on Thursday, August 1st. Finally, StockNews.com cut shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $12.00.

MiMedx Group Stock Performance

Shares of NASDAQ:MDXG opened at $9.23 on Wednesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. The business’s fifty day moving average price is $6.72 and its two-hundred day moving average price is $6.86. MiMedx Group, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $9.49. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of 16.78 and a beta of 1.94.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.